Volume 27, Issue 4 (7-2023)                   IBJ 2023, 27(4): 167-172 | Back to browse issues page


XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Akrami H, Gholami H, Fattahi M R, Zeraatiannejad M. Effect of miR-4270 Suppression on Migration in Hepatocellular Carcinoma Cell Line (HepG2). IBJ 2023; 27 (4) :167-172
URL: http://ibj.pasteur.ac.ir/article-1-3923-en.html
Abstract:  
Background: Liver transplantation and surgical resection are two major strategies for treatment of hepatocellular carcinoma (HCC) patients. One approach to treating HCC is the suppression of metastasis to other tissues. Herein, we aimed to study the effect of miR-4270 inhibitor on migration of HepG2 cells as well as activity of matrix metalloproteinase (MMP) these cells in order to find a strategy to suppress metastasis in future.
Methods: HepG2 cells were treated with 0, 10, 20, 30, 40, 50, 60, 70, 80, and 90 nM of miR-4270 inhibitor, and then the cell viability was measured by trypan blue staining. Afterwards, cell migration and MMP activity of HepG2 cells were assessed by wound healing assay and zymography, respectively. The MMP gene expression was determined by real-time reverse transcription polymerase chain reaction.
Results: Results showed that miR-4270 inhibitor decreased the cell viability of HepG2 cells in a concentration-dependent manner. Also, inhibition of the miR-4270 reduced invasion, MMP activity, and expression of MMP genes in HepG2 cells, respectively.
Conclusion: Our findings suggest that miR-4270 inhibitor decreases in vitro migration, which could help find a new approach for HCC therapy patients.
Type of Study: Full Length/Original Article | Subject: Cancer Biology

References
1. McGlynn KA, Petrick JL, ElSerag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2021; 73(Suppl 1): 4-13. [DOI:10.1002/hep.31288]
2. Ogunwobi OO, Harricharran T, Huaman J, Anna Galuza, Odumuwagun O, Tan Y, Ma GX, Nguyen MT. Mechanisms of hepatocellular carcinoma progression. World journal of gastroenterology 2019; 25(19): 2279-2293. [DOI:10.3748/wjg.v25.i19.2279]
3. Bose PP, Chatterjee U. Advances in early diagnosis of hepatocellular carcinoma. Hepatoma research 2019; 5(24): 1-9. [DOI:10.20517/2394-5079.2019.10]
4. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nature genetics 2003; 33: 49-54. [DOI:10.1038/ng1060]
5. Cao Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Advances in cancer research 2008; 100: 113-131. [DOI:10.1016/S0065-230X(08)00004-3]
6. Xia M, Hu M. The Role of microRNA in tumor invasion and metastasis. Journal of cancer molecules 2010; 5(2): 33-39.
7. Miroshnichenko S, Patutina O. Enhanced inhibition of tumorigenesis using combinations of miRNA-Targeted Therapeutics. Frontier in pharmacology 2019; 10(488): 1-17. [DOI:10.3389/fphar.2019.00488]
8. Wang H, Huang Z, Zhao X, Guo B, Ji Z. miR-4270 regulates cell proliferation and apoptosis in patients with Sertoli cell-only syndrome by targeting GADD45A and inactivating the NOTCH signaling pathway. American journal of translational research 2020; 12(9): 5730.
9. Zhu HR, Huang RZ, Yu XN, Shi X, Bilegsaikhan E, Guo HY, Song GQ, Weng SQ, Dong L, Janssen HLA, Shen XZ, Zhu JM. Microarray expression profling of microRNAs reveals potential biomarkers for hepatocellular carcinoma. Tohoku journal of experimental medicine 2018; 245(2): 89-98. [DOI:10.1620/tjem.245.89]
10. Morishita A, Oura K, Tadokoro T, Fujita K, Tani J, Masaki T. MicroRNAs in the pathogenesis of hepatocellular carcinoma: A review. Cancers 2021; 13(514): 1-29. [DOI:10.3390/cancers13030514]
11. Aminisepehr F, Babaei E, Hosseinpour Feizi MA. Study of the expression of miR-4270 in plasma of patients with breast invasive ductal carcinoma. Journal of genetic resources 2018; 4(2): 85-89.
12. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, Lao KQ, Livak KJ, Guegler KJ. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic acids research 2005; 33(20): e179. [DOI:10.1093/nar/gni178]
13. Paolis VD, Lorefice E, Orecchini E, Carissimi C, Laudadio I, Fulci V. Epitranscriptomics: A new layer of microRNA regulation in cancer. Cancers 2021; 13(13): 3372. [DOI:10.3390/cancers13133372]
14. Cheerla N, Gevaert O. MicroRNA based Pan-Cancer diagnosis and treatment recommendation. BMC bioinformatics 2017; 18(32): 1-11. [DOI:10.1186/s12859-016-1421-y]
15. Xiang Y, Tian Q, Guan L, Niu SS. The Dual role of miR-186 in cancers: oncomir battling with tumor suppressor miRNA. Frontier in oncology 2020; 10(233): 1-11. [DOI:10.3389/fonc.2020.00233]
16. Zou A, Liu X, Mai Z, Zhang J, Liu Z, Huang Q, Wu A, Zhou C. LINC00472 acts as a tumor suppressor in NSCLC through KLLN-mediated p53-signaling pathway via microRNA-149-3p and microRNA-4270. Molecular therapy nucleic acids 2019; 17: 563-577. [DOI:10.1016/j.omtn.2019.06.003]
17. Hao W, Zhu Y, Wang H, Guo Y. miR-4270 modulates the irradiation-sensitivity of nasopharyngeal carcinoma cells through modulation of p53 in vivo. Tohoku journal of experimental medicine 2021; 254(2): 63-70. [DOI:10.1620/tjem.254.63]
18. Feng W, Zhu R, Ma J, Song H. LncRNA ELFN1-AS1 promotes retinoblastoma growth and invasion via regulating miR-4270/ SBK1 axis. Cancer management and research 2021; 13: 1067-1073. [DOI:10.2147/CMAR.S281536]
19. Aminisepehr F, Babaei E, Feizi MAH. Study of the expression of miR-4270 in plasma of patients with breast invasive ductal carcinoma. Journal of genetics resources 2018; 4(2): 85-89.
20. Hamam R, Ali AM, Alsaleh KA, Kassem M, Alfayez M, Aldahmash A, Alajez NM. microRNA expression profling on individual breast cancer patients identifes novel panel of circulating microRNA for early detection. Scientific reports 2016; 6(25997): 1-8. [DOI:10.1038/srep25997]
21. Sun G, Ding X, Bi N, Wang Z, Wu L, Zhou W, Zhao Z, Wang J, Zhang W, Fan J, Zhang W, Dong X, Lv N, Song L, Zhan Q, Wang L. Molecular predictors of brain metastasisrelated microRNAs in lung adenocarcinoma. PLoS genet 2019; 15(2): e1007888. [DOI:10.1371/journal.pgen.1007888]
22. Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, Shibata C, Koike K. The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects. Journal of gastroenterology 2014; 49: 173-184. [DOI:10.1007/s00535-013-0909-8]
23. Wang Y, Li Cf, Sun Lb, Li Yc. microRNA-4270-5p inhibits cancer cell proliferation and metastasis in hepatocellular carcinoma by targeting SATB2. Human cell 2020; 33(4): 1155-1164. [DOI:10.1007/s13577-020-00384-0]
24. Choudhary NS, Duseja A. Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). translational gastroenterology and hepatology 2021; 6(2): 1-17. [DOI:10.21037/tgh.2019.09.06]
25. Zhou D, Dong L, Yang L, Ma Q, Liu F, Li Y, Xiong S. identification and analysis of circRNA- miRNA-mRNA regulatory network in hepatocellular carcinoma. IET systems biology 2020; 14(6): 391-398. [DOI:10.1049/iet-syb.2020.0061]
26. Shen D, Zhao H, Zeng P, Song J, Yang Y, Gu X. Circular RNA hsa_circ_0005556 accelerates gastric cancer progression by sponging miR-4270 to increase MMP19 expression. Joural of gastric cancer 2020; 20(3): 300-312. [DOI:10.5230/jgc.2020.20.e28]
27. Tokuhisa M, Ichikawa Y, Kosaka N, Ochiya T, Yashiro; M, Hirakawa K, Kosaka T, Makino H, Akiyama H, Kunisaki C, Endo I. Exosomal miRNAs from peritoneum lavage fluid as potential prognostic biomarkers of peritoneal metastasis in gastric cancer. Plos one 2015; 10(7): e0130472. [DOI:10.1371/journal.pone.0130472]
28. Pagliari M, Munari F, Toffoletto M, Lonardi S, Chemello F, Codolo G et al. Helicobacter pylori affects the antigen presentation activity of macrophages modulating the expression of the immune receptor cD300e through mir-4270. Frontier in immunology 2017; 8(1288): 1-12. [DOI:10.3389/fimmu.2017.01288]

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb